A report from the USC-led AI initiative highlights continued NIH investment into Alzheimer’s code-cracking efforts, while separate regulatory and pipeline developments show broader momentum toward gene-based and molecular therapies. In one key regulatory example, China’s NMPA approved a new clinical trial in China for Fosun’s FXB-0871 (TEV-56278) in locally advanced or metastatic solid tumors. These moves reflect continued global expansion of clinical discovery beyond the US/EU and reinforce the role of regulator-backed trials for translating new targets into first-in-human or early clinical evidence. For biopharma, the take-away is that pipeline progression is increasingly tied to local regulatory clearances and to partnerships that support rapid trial start-up.